<ul>
<li>Lonza annual report for fiscal 2025 highlighted continued execution of One Lonza strategy, positioning group as a pure-play CDMO.     *      Group agreed to divest Capsules &amp; Health Ingredients for enterprise value of CHF 2.3 billion, with closing expected in H2 2026.     *      Operating model shifted to three CDMO business platforms in April 2025 to streamline delivery across Integrated Biologics, Advanced Synthesis, Specialized Modalities.     *      Performance was driven by strong demand in biologics, supported by ramp-up of growth projects such as Visp expansions.     *      Board planned dividend proposal of CHF 5 per share for May 2026 AGM. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lonza Group Ltd. published the original content used to generate this news brief via Singapore Exchange Limited (SGX) (Ref. ID: LJE7WPRJD5EBVAED) on April 01, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here</li>
</ul>

SBIO

LABU

LZAGY

<p>Lonza's 2025 annual report reveals progress in its transformation into a pure-play CDMO, with a divestment of Capsules & Health Ingredients for CHF 2.3 billion expected to close in H2 2026. The company has shifted to three CDMO business platforms to enhance delivery in Integrated Biologics, Advanced Synthesis, and Specialized Modalities. Strong demand in biologics and growth projects like Visp expansions contributed to performance. A dividend proposal of CHF 5 per share is planned for the May 2026 AGM.</p>

Lonza publishes 2025 annual report as pure-play CDMO transformation advances